Log in

Company updateCNBC-TV18

Cipla InvaGen facility gets USFDA No Action Indicated

Positive+18

GreyOak summary

Cipla's US subsidiary InvaGen received a 'No Action Indicated' classification from the USFDA following an inspection from October 19 to 22, 2026. This indicates no violations were observed, allowing the facility to continue selling approved drugs and pursue new filings.

What it affects

  • CiplaCIPLAPositive +18

    USFDA inspection resulted in No Action Indicated.Rolling sentiment Neutral -13

Source

Read the original at CNBC-TV18

More Cipla news

All Cipla news →

We use cookies

Essential cookies keep GreyOak secure and functional. Optional cookies help improve your experience and platform performance. You can update your preferences anytime.

Cookie Policy